Antibiotic Treatment for Haemophilus influenzae Infections

Introduction to Antibiotic Choices

The American Academy of Pediatrics recommends amoxicillin-clavulanate as the antibiotic of choice for H. influenzae infections due to its activity against beta-lactamase-producing strains, which account for up to 17.6% of isolates in Europe 1
The European Respiratory Society suggests that amoxicillin-clavulanate provides optimal coverage against both beta-lactamase-producing and non-producing strains, with a recommended dosing of 90 mg/kg/day of amoxicillin with 6.4 mg/kg/day of clavulanate in 2 divided doses for pediatric patients, or 500-1000 mg every 8 hours for adults 2, 3

The American Academy of Otolaryngology-Head and Neck Surgery recommends amoxicillin alone (500-1000 mg every 8 hours) for beta-lactamase-negative strains, but notes that plain amoxicillin achieves only 70-85% activity against H. influenzae using pharmacokinetic/pharmacodynamic breakpoints 2, 4
The European Respiratory Society suggests that ceftriaxone (1 g IV every 24 hours or 50 mg IM/IV for 3 days) provides 95-100% activity against H. influenzae and ensures adequate tissue concentrations, making it a suitable option for severe or hospitalized cases 5, 4, 3

The Clinical Microbiology and Infection society notes that beta-lactamase production is the primary resistance mechanism, varying geographically from 0.7-17.6% in Europe, with a mean prevalence of 7.6% 6, 1, 7
The American Academy of Pediatrics recommends avoiding plain amoxicillin, ampicillin, and first-generation cephalosporins in areas with high beta-lactamase production (>10%) 1, 7

The Clinical Microbiology and Infection society states that macrolides are generally ineffective for H. influenzae despite appearing active in vitro, due to macrolide efflux mechanisms rendering azithromycin, clarithromycin, and erythromycin unreliable 6, 1, 8

The European Respiratory Society recommends treating for at least 7 days for respiratory tract infections, and assessing clinical response at days 5-7 for outpatient management 2, 5
The European Respiratory Society also suggests reassessing hospitalized pneumonia cases at days 2-3 for fever resolution and lack of radiographic progression 5, 9

Alterations in penicillin‑binding proteins (PBP 3a and PBP 3b) confer chromosomal resistance to aminopenicillins and some cephalosporins, even when β‑lactamase testing is negative. (Laboratory evidence) 10, 11
>98 % of H. influenzae isolates carry chromosomally‑mediated acrAB efflux pumps that expel macrolides, making macrolides/azalides clinically ineffective despite apparent in‑vitro activity. (Laboratory evidence) 10, 11

Plain amoxicillin or ampicillin are ineffective against BLNAR strains because intrinsic resistance to aminopenicillins exists independent of β‑lactamase production. (Clinical microbiology data) 12, 13
The European Respiratory Society guidelines identify β‑lactamase production as a well‑known predictor of treatment failure in community‑acquired respiratory tract infections. (Guideline recommendation) 12

Mean prevalence of BLNAR strains in Europe is 7.6 % (range 0.7‑17.6 %). (Epidemiologic surveys) 12, 13
The American Academy of Otolaryngology‑Head and Neck Surgery notes that BLNAR strains are rare in the United States but represent a significant concern where they are present. (Society statement) 10, 11